title: [Modulation of the antitumor effect of cyclophosphamide by the recombinant probiotic Subalin].
abstract: A new preparation "subalin" developed on the basis of a recombinant saprophyte strain of Bacillus subtilis 2135/105 producing human interferon alpha-2 has been tested for its ability of increasing the effectiveness of antitumor therapy. The study used Lewis lung carcinoma bearing mice C57B1/6 treated with injections of 60 mg/kg body cyclophosphamide, intraperitoneally, on days 3 and 7 of tumor growth. Subalin was administered per as on days 1-14 after tumor transplantation. Combined treatment with cyclophosphamide and subalin resulted in a significantly higher inhibition of primary tumor growth and metastatic spreading as compared with control receiving cyclophosphamide alone. Also, there were fewer animals with metastasis; the average number of these lesions per animal and the total affected area were less. Subalin proved to exert a moderate antitumor and antimetastatic effect. The cytostatic activity of peritoneal macrophages was higher in mice treated with subalin. It is suggested that the chemo-sensitizing and antitumor effects of subalin are due to its ability to induce endogenous interferon production.
authors.forename: N V
authors.initials: NV
authors.lastname: Cherdyntseva
authors.forename: N V
authors.initials: NV
authors.lastname: Litviakov
authors.forename: E S
authors.initials: ES
authors.lastname: Smol'ianinov
authors.forename: V A
authors.initials: VA
authors.lastname: Beliavskaia
authors.forename: V I
authors.initials: VI
authors.lastname: Masycheva
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D003520:Cyclophosphamide / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D007370:Interferon Type I / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D011994:Recombinant Proteins
chemical_list: D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D007370:Interferon Type I; D011994:Recombinant Proteins; D003520:Cyclophosphamide
vernacular_title: Moduliatsiia protivoopukholevoĭ aktivnosti tsiklofosfana rekombinantnym probiotikom Subalinom.